{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kilchrist KV"],"funding":["NEI NIH HHS","NIBIB NIH HHS","NIDDK NIH HHS","U.S. Department of Health and Human Services","NHLBI NIH HHS","U.S. Department of Defense","NCI NIH HHS","Vanderbilt University","National Science Foundation"],"pagination":["1136-1152"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6995262"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(2)"],"pubmed_abstract":["Endolysosome entrapment is one of the key barriers to the therapeutic use of biologic drugs that act intracellularly. The screening of prospective nanoscale endosome-disrupting delivery technologies is currently limited by methods that are indirect and cumbersome. Here, we statistically validate Galectin 8 (Gal8) intracellular tracking as a superior approach that is direct, quantitative, and predictive of therapeutic cargo intracellular bioactivity through in vitro high-throughput screening and in vivo validation. Gal8 is a cytosolically dispersed protein that, when endosomes are disrupted, redistributes by binding to glycosylation moieties selectively located on the inner face of endosomal membranes. The quantitative redistribution of a Gal8 fluorescent fusion protein from the cytosol int"],"journal":["ACS nano"],"pubmed_title":["Gal8 Visualization of Endosome Disruption Predicts Carrier-Mediated Biologic Drug Intracellular Bioavailability."],"pmcid":["PMC6995262"],"funding_grant_id":["R01CA224241","U24 DK059637","DGE-1445197","P30 DK058404","R01 EB019409","DGE-0909667","proposal number OR130302","P30 EY008126","R01 CA224241","P30 DK020593","R01EB019409","W81XWH-14-1-0298","P30 CA068485","U2C DK059637","R01 HL122347","R01HL122347"],"pubmed_authors":["Kilchrist KV","Jackson MA","Duvall CL","Evans BC","Bedingfield SK","Kelly IB","Werfel TA","Dailing EA","Dimobi SC"],"additional_accession":[]},"is_claimable":false,"name":"Gal8 Visualization of Endosome Disruption Predicts Carrier-Mediated Biologic Drug Intracellular Bioavailability.","description":"Endolysosome entrapment is one of the key barriers to the therapeutic use of biologic drugs that act intracellularly. The screening of prospective nanoscale endosome-disrupting delivery technologies is currently limited by methods that are indirect and cumbersome. Here, we statistically validate Galectin 8 (Gal8) intracellular tracking as a superior approach that is direct, quantitative, and predictive of therapeutic cargo intracellular bioactivity through in vitro high-throughput screening and in vivo validation. Gal8 is a cytosolically dispersed protein that, when endosomes are disrupted, redistributes by binding to glycosylation moieties selectively located on the inner face of endosomal membranes. The quantitative redistribution of a Gal8 fluorescent fusion protein from the cytosol int","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Feb","modification":"2025-04-19T09:34:32.5Z","creation":"2020-05-22T10:50:06Z"},"accession":"S-EPMC6995262","cross_references":{"pubmed":["30629431"],"doi":["10.1021/acsnano.8b05482"]}}